Ciclesonide

Title: Ciclesonide
CAS Registry Number: 126544-47-6
CAS Name: (11b,16a)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione
Manufacturers' Codes: BY-9010
Trademarks: Alvesco (Altana)
Molecular Formula: C32H44O7
Molecular Weight: 540.69
Percent Composition: C 71.08%, H 8.20%, O 20.71%
Literature References: Inhaled corticosteroid. Prodrug converted to the active metabolite, ciclesonide-active principle, in the lung. Prepn: J. Calatayud et al., DE 4129535; eidem, US 5482934 (1992, 1996 both to Elmu). Pharmacokinetics and pharmacodynamics: S. Rohatagi et al., J. Clin. Pharmacol. 43, 365 (2003). Clinical evaluation in asthma: D. A. Taylor et al., Am. J. Respir. Crit. Care Med. 160, 237 (1999); in allergic rhinitis: B. M. W. Schmidt et al., J. Clin. Pharmacol. 39, 1062 (1999). Review of clinical experience: G. Dent, Curr. Opin. Invest. Drugs 3, 78-83 (2002).
Therap-Cat: Glucocorticoid.
Keywords: Glucocorticoid.
Cicletanine Ciclonicate Ciclopirox Ciclosidomine Cicrotoic Acid

Ciclesonide
Ciclesonide.svg
Ciclesonide ball-and-stick animation.gif
Systematic (IUPAC) name
2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a607008
Pregnancy cat. B3 (AU) C (US)
Legal status Prescription Only (S4) (AU) POM (UK) -only (US)
Routes nasal inhalation
Identifiers
CAS number 141845-82-1 YesY
ATC code R01AD13 R03BA08
PubChem CID 6918155
DrugBank DB01410
ChemSpider 5293368 YesY
UNII S59502J185 YesY
KEGG D01703 YesY
ChEMBL CHEMBL1201164 N
Synonyms (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
Chemical data
Formula C32H44O7 
Mol. mass 540.688 g/mol
 N (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand name Alvesco for asthma and Omnaris/Omniair for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[3]